TELCON RF PHARMACEUTICAL. Statistics
Total Valuation
TELCON RF PHARMACEUTICAL. has a market cap or net worth of KRW 71.91 billion. The enterprise value is 108.68 billion.
Market Cap | 71.91B |
Enterprise Value | 108.68B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
Earnings Date | Mar 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TELCON RF PHARMACEUTICAL. has 12.03 million shares outstanding. The number of shares has decreased by -17.91% in one year.
Current Share Class | n/a |
Shares Outstanding | 12.03M |
Shares Change (YoY) | -17.91% |
Shares Change (QoQ) | +3.00% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.47% |
Float | 9.19M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.89 |
PB Ratio | 0.76 |
P/TBV Ratio | 0.95 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -10.82 |
EV / Sales | 2.94 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -40.82 |
Financial Position
The company has a current ratio of 0.31, with a Debt / Equity ratio of 0.45.
Current Ratio | 0.31 |
Quick Ratio | 0.17 |
Debt / Equity | 0.45 |
Debt / EBITDA | 11.67 |
Debt / FCF | -16.12 |
Interest Coverage | -0.31 |
Financial Efficiency
Return on equity (ROE) is -10.43% and return on invested capital (ROIC) is -0.34%.
Return on Equity (ROE) | -10.43% |
Return on Assets (ROA) | -0.32% |
Return on Capital (ROIC) | -0.34% |
Revenue Per Employee | 290.96M |
Profits Per Employee | -79.12M |
Employee Count | 127 |
Asset Turnover | 0.26 |
Inventory Turnover | 5.01 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.11% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -42.11% |
50-Day Moving Average | 5,774.60 |
200-Day Moving Average | 6,951.10 |
Relative Strength Index (RSI) | 57.96 |
Average Volume (20 Days) | 43,910 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TELCON RF PHARMACEUTICAL. had revenue of KRW 36.95 billion and -10.05 billion in losses. Loss per share was -862.34.
Revenue | 36.95B |
Gross Profit | 9.08B |
Operating Income | -708.58M |
Pretax Income | -10.09B |
Net Income | -10.05B |
EBITDA | 3.68B |
EBIT | -708.58M |
Loss Per Share | -862.34 |
Balance Sheet
The company has 6.45 billion in cash and 42.90 billion in debt, giving a net cash position of -36.46 billion or -3,031.74 per share.
Cash & Cash Equivalents | 6.45B |
Total Debt | 42.90B |
Net Cash | -36.46B |
Net Cash Per Share | -3,031.74 |
Equity (Book Value) | 95.53B |
Book Value Per Share | 7,918.47 |
Working Capital | -38.92B |
Cash Flow
In the last 12 months, operating cash flow was 1.69 billion and capital expenditures -4.35 billion, giving a free cash flow of -2.66 billion.
Operating Cash Flow | 1.69B |
Capital Expenditures | -4.35B |
Free Cash Flow | -2.66B |
FCF Per Share | -221.40 |
Margins
Gross margin is 24.56%, with operating and profit margins of -1.92% and -27.19%.
Gross Margin | 24.56% |
Operating Margin | -1.92% |
Pretax Margin | -27.30% |
Profit Margin | -27.19% |
EBITDA Margin | 9.95% |
EBIT Margin | -1.92% |
FCF Margin | n/a |
Dividends & Yields
TELCON RF PHARMACEUTICAL. does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 17.91% |
Shareholder Yield | 17.91% |
Earnings Yield | -14.42% |
FCF Yield | -3.70% |
Stock Splits
The last stock split was on August 12, 2016. It was a forward split with a ratio of 5.
Last Split Date | Aug 12, 2016 |
Split Type | Forward |
Split Ratio | 5 |
Scores
TELCON RF PHARMACEUTICAL. has an Altman Z-Score of -0.68. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.68 |
Piotroski F-Score | n/a |